Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) recently experienced a sharp pullback for biotech investors
Shares of biopharmaceutical company Alnylam Pharmaceuticals (ALNY) dropped around 20–25% over the past week following unexpected market adjustments and clinical data shifts. While biotechnology stocks offer significant growth potential, their inherent volatility makes them particularly high-risk.
Biotech stocks are sensitive to pipeline results and regulatory updates. If your financial advisor placed a large portion of your retirement savings or liquid portfolio into ALNY—or the broader biotech sector—without proper diversification, you may have been exposed to unnecessary risk. Advisors have a duty to recommend a balanced strategy suited to your risk tolerance.
Options for Recovering Losses
If your advisor failed to manage risk or over-concentrated your account in volatile single stocks like ALNY, you can file a claim through the Financial Industry Regulatory Authority (FINRA) agasint the broker and/or firm..
Brokerage firms are legally required under FINRA Rule 3110 to monitor advisor activity and enforce concentration limits. If the firm failed to flag your account's over-concentration, the firm itself may be liable for your financial recovery.
October 29, 2026